SG11201601221XA - Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins - Google Patents
Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteinsInfo
- Publication number
- SG11201601221XA SG11201601221XA SG11201601221XA SG11201601221XA SG11201601221XA SG 11201601221X A SG11201601221X A SG 11201601221XA SG 11201601221X A SG11201601221X A SG 11201601221XA SG 11201601221X A SG11201601221X A SG 11201601221XA SG 11201601221X A SG11201601221X A SG 11201601221XA
- Authority
- SG
- Singapore
- Prior art keywords
- proteins
- compositions
- recombinant human
- clotting factor
- heterogeneous populations
- Prior art date
Links
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Water Supply & Treatment (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361881834P | 2013-09-24 | 2013-09-24 | |
PCT/IB2014/064564 WO2015044836A1 (en) | 2013-09-24 | 2014-09-16 | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201601221XA true SG11201601221XA (en) | 2016-04-28 |
Family
ID=51844797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201601221XA SG11201601221XA (en) | 2013-09-24 | 2014-09-16 | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
Country Status (19)
Country | Link |
---|---|
US (3) | US9757434B2 (pt) |
EP (1) | EP3049434A1 (pt) |
JP (1) | JP6429885B2 (pt) |
KR (1) | KR101988705B1 (pt) |
CN (2) | CN105579468A (pt) |
AR (1) | AR097732A1 (pt) |
AU (1) | AU2014326257B2 (pt) |
BR (1) | BR112016005899A8 (pt) |
CA (1) | CA2924981C (pt) |
HK (1) | HK1218760A1 (pt) |
IL (2) | IL244258A0 (pt) |
MX (1) | MX2016003871A (pt) |
MY (1) | MY173548A (pt) |
PE (1) | PE20160877A1 (pt) |
RU (1) | RU2648144C2 (pt) |
SA (1) | SA516370751B1 (pt) |
SG (1) | SG11201601221XA (pt) |
TW (1) | TWI631134B (pt) |
WO (1) | WO2015044836A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2015008813A (es) | 2013-01-31 | 2016-03-31 | Pfizer | Composiciones y metodos para contrarrestar la inhibicion del factor xa. |
WO2015044836A1 (en) | 2013-09-24 | 2015-04-02 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
CA3027457A1 (en) | 2016-06-17 | 2017-12-21 | Portola Pharmaceuticals, Inc. | Preparation of factor xa derivatives |
EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
US20040102388A1 (en) | 2000-03-22 | 2004-05-27 | High Katherine A. | Modified blood clotting factors and methods of use |
FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
KR20070043051A (ko) | 2004-08-17 | 2007-04-24 | 쳇엘베 베링 게엠베하 | 변형된 비타민 k 의존적 폴리펩타이드 |
EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
CN102559644B (zh) * | 2007-09-28 | 2015-03-25 | 普托拉制药有限公司 | 用于因子xa抑制剂的解毒剂和其使用方法 |
KR101804136B1 (ko) | 2008-06-24 | 2017-12-04 | 옥타파마 아게 | 응고 인자 viii을 정제하는 방법 |
NZ592837A (en) * | 2008-11-14 | 2012-10-26 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
ES2629099T3 (es) | 2008-12-19 | 2017-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea |
JP6163304B2 (ja) | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子インヒビターの解毒剤の単位用量処方物およびその使用方法 |
PL2591006T3 (pl) * | 2010-07-09 | 2019-10-31 | Bioverativ Therapeutics Inc | Przetwarzalne cząsteczki jednołańcuchowe i polipeptydy wytworzone przy ich zastosowaniu |
FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
EP2760887A4 (en) | 2011-09-30 | 2015-06-10 | Philadelphia Children Hospital | COMPOSITIONS AND METHODS OF HEMOSTASE MODULATION |
EA028865B1 (ru) | 2012-07-25 | 2018-01-31 | Каталист Биосайенсиз, Инк. | Модифицированные полипептиды фактора х и их применение |
MX2015008813A (es) | 2013-01-31 | 2016-03-31 | Pfizer | Composiciones y metodos para contrarrestar la inhibicion del factor xa. |
WO2015044836A1 (en) | 2013-09-24 | 2015-04-02 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
WO2015066606A2 (en) | 2013-11-01 | 2015-05-07 | The Children's Hospital Of Philadelphia | Compositions and methods for increasing the half-life of factor xa |
CA2937418A1 (en) | 2014-01-24 | 2015-07-30 | Pfizer Inc. | Compositions and methods for treating intracerebral hemorrhage |
-
2014
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en active Application Filing
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko active IP Right Grant
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 MX MX2016003871A patent/MX2016003871A/es active IP Right Grant
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-24 US US14/495,478 patent/US9757434B2/en active Active
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
- 2016-06-10 HK HK16106674.2A patent/HK1218760A1/zh unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SA516370751B1 (ar) | 2018-04-05 |
CN105579468A (zh) | 2016-05-11 |
JP2016535071A (ja) | 2016-11-10 |
US20170333535A1 (en) | 2017-11-23 |
US20150182604A1 (en) | 2015-07-02 |
AR097732A1 (es) | 2016-04-13 |
AU2014326257A1 (en) | 2016-03-10 |
US10660946B2 (en) | 2020-05-26 |
TWI631134B (zh) | 2018-08-01 |
EP3049434A1 (en) | 2016-08-03 |
WO2015044836A1 (en) | 2015-04-02 |
US9757434B2 (en) | 2017-09-12 |
KR101988705B1 (ko) | 2019-06-12 |
JP6429885B2 (ja) | 2018-11-28 |
IL279396A (en) | 2021-01-31 |
TW201524996A (zh) | 2015-07-01 |
HK1218760A1 (zh) | 2017-03-10 |
CA2924981C (en) | 2020-03-31 |
CN112195169A (zh) | 2021-01-08 |
AU2014326257B2 (en) | 2017-08-10 |
CA2924981A1 (en) | 2015-04-02 |
MY173548A (en) | 2020-02-04 |
BR112016005899A8 (pt) | 2018-02-06 |
BR112016005899A2 (pt) | 2017-09-26 |
PE20160877A1 (es) | 2016-09-11 |
RU2648144C2 (ru) | 2018-03-22 |
RU2016108608A (ru) | 2017-10-26 |
US20210106658A1 (en) | 2021-04-15 |
KR20160044034A (ko) | 2016-04-22 |
IL244258A0 (en) | 2016-04-21 |
MX2016003871A (es) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281703A (en) | New heterodimeric proteins | |
HRP20190454T1 (hr) | Rekombinantni faktor viii proteini | |
HK1219964A1 (zh) | 治療性蛋白藥物物質的整合連續製造 | |
IL279396A (en) | Preparations containing heterogeneous populations of recombinant human coagulation factor XA proteins | |
DK3415525T3 (da) | Amfipatisk peptid | |
SG11201603028SA (en) | Purification of proteins | |
EP2802654A4 (en) | PREPARATION OF RECOMBINANT PROTEINS WITH SIMPLE GLYCO FORMS | |
HK1217167A1 (zh) | 用於誘導對凝固因子蛋白的免疫耐受的組合物 | |
SG11201507276UA (en) | Improved methods of use for recombinant human secretoglobins | |
BR112014023176A2 (pt) | Métodos de produção de uma proteína recombinante | |
HK1216715A1 (zh) | 基於血紅蛋白衍生肽的新型藥物組合物 | |
IL241417A0 (en) | Modification and new compositions of human scartoglobin proteins | |
SG10201507721SA (en) | CHO-GMT Recombinant Protein Expression | |
HK1205147A1 (en) | Truncated l1 proteins of human papillomavirus type 45 45 l1 | |
EP3560952C0 (en) | VARIANT OF BPIFB4 PROTEIN | |
GB201304973D0 (en) | Recombinant protein | |
EP2978770A4 (en) | REINFORCEMENT OF PROTEINS | |
TWM476490U (en) | Bonding structure of false eyelashes | |
EP2970916A4 (en) | LEPIDOPTER INSECT CELLS SUITABLE FOR THE PRODUCTION OF RECOMBINANT PROTEINS | |
HK1211952A1 (en) | Recombinant protein | |
GB201321911D0 (en) | N-Glycosylation of peptides and proteins | |
GB201318313D0 (en) | N-Glycosylation of peptides and proteins | |
TWM475688U (en) | Improved structure of program switch | |
UA24071S (uk) | Набір столових приборів | |
UA26527S (uk) | Комплект посуду |